Brain atrophy and patch-based grading in individuals from the CIMA-Q study : a progressive continuum from subjective cognitive decline to AD

Élément Dublin CoreValeurLangue
dc.contributor.authorMarcotte, Christine-
dc.contributor.authorPotvin, Olivier-
dc.contributor.authorDuchesne, Simon-
dc.date.accessioned2020-10-26T10:58:25Z-
dc.date.available2020-10-26T10:58:25Z-
dc.date.issued2019-09-19-
dc.identifier.issn2045-2322fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/67013-
dc.description.abstractIt has been proposed that individuals developing Alzheimer’s disease (AD) first experience a phase expressing subjective complaints of cognitive decline (SCD) without objective cognitive impairment. Using magnetic resonance imaging (MRI), our objective was to verify whether SNIPE probability grading, a new MRI analysis technique, would distinguish between clinical dementia stage of AD: Cognitively healthy controls without complaint (CH), SCD, mild cognitive impairment, and AD. SNIPE score in the hippocampus and entorhinal cortex was applied to anatomical T1-weighted MRI of 143 participants from the Consortium pour l’identification précoce de la maladie Alzheimer - Québec (CIMA-Q) study and compared to standard atrophy measures (volumes and cortical thicknesses). Compared to standard atrophy measures, SNIPE score appeared more sensitive to differentiate clinical AD since differences between groups reached a higher level of significance and larger effect sizes. However, no significant difference was observed between SCD and CH groups. Combining both types of measures did not improve between-group differences. Further studies using a combination of biomarkers beyond anatomical MRI might be needed to identify individuals with SCD who are on the beginning of the clinical continuum of AD.fr
dc.languageengfr
dc.publisherNature Publishing Groupfr
dc.subjectAlzheimer's diseasefr
dc.subjectPredictive markersfr
dc.titleBrain atrophy and patch-based grading in individuals from the CIMA-Q study : a progressive continuum from subjective cognitive decline to ADfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationScientific Reports, Vol. 9 (1), 1-10 (2019)fr
dc.identifier.doi10.1038/s41598-019-49914-3fr
dc.subject.rvmMaladie d'Alzheimer -- Imagerie par résonance magnétiquefr
dc.subject.rvmAtrophie cérébralefr
dc.subject.rvmMarqueurs biologiquesfr
rioxxterms.versionVersion of Recordfr
rioxxterms.version_of_recordhttps://doi.org/10.1038/s41598-019-49914-3fr
rioxxterms.project.funder_nameFonds de recherche du Québec – Santé / Pfizer Canadafr
rioxxterms.project.funder_nameAlzheimer Societyfr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
ali.license_refAttribution CC BYfr
ali.license_ref.start_date2020-10-22fr
bul.rights.periodeEmbargo0 moisfr
dc.audience.peerreviewOuifr
Collection :Articles publiés dans des revues avec comité de lecture

Fichier(s) :
Description TailleFormat 
Marcotte19a.pdf2.1 MBAdobe PDFMiniature
Télécharger
Tous les documents dans CorpusUL sont protégés par la Loi sur le droit d'auteur du Canada.